- 全部删除
 您的购物车当前为空 您的购物车当前为空
Sumatriptan (GR 43175 free base) 是一种可穿过血脑屏障且具有口服活性和高效性的5-羟色胺1(5-HT1) 受体激动剂,具有抗炎活性,对 5-HT1D、5-HT1B 和 5-HT1F 受体具有较高亲和力,可用于急性偏头痛和急性心肌梗死。

Sumatriptan (GR 43175 free base) 是一种可穿过血脑屏障且具有口服活性和高效性的5-羟色胺1(5-HT1) 受体激动剂,具有抗炎活性,对 5-HT1D、5-HT1B 和 5-HT1F 受体具有较高亲和力,可用于急性偏头痛和急性心肌梗死。
| 规格 | 价格 | 库存 | 数量 | 
|---|---|---|---|
| 5 mg | ¥ 283 | In stock | |
| 10 mg | ¥ 395 | In stock | |
| 25 mg | ¥ 662 | In stock | |
| 50 mg | ¥ 983 | In stock | |
| 100 mg | ¥ 1,450 | In stock | |
| 500 mg | ¥ 3,630 | In stock | |
| 1 mL x 10 mM (in DMSO) | ¥ 728 | In stock | 
Sumatriptan 相关产品
| 产品描述 | Sumatriptan (GR 43175 free base) is an orally active and potent 5-hydroxytryptamine 1 (5-HT1) receptor agonist that crosses the blood-brain barrier and has anti-inflammatory activity with high affinity for 5-HT1D, 5-HT1B, and 5-HT1F receptors for use in acute migraines and acute myocardial infarction. | 
| 靶点活性 |  5-HT1F Receptor:17.8 nM, 5-HT1A Receptor:100 nM (Ki), 5-HT1B Receptor:9.3 nM, 5-HT1B Receptor:27 nM (Ki), 5-HT1D Receptor:17 nM (Ki), 5-HT1D Receptor:7.3 nM (IC50) | 
| 别名 | 舒马曲坦, GR 43175 free base | 
| 分子量 | 295.4 | 
| 分子式 | C14H21N3O2S | 
| CAS No. | 103628-46-2 | 
| Smiles | O=S(=O)(NC)CC=1C=CC=2NC=C(C2C1)CCN(C)C | 
| 密度 | 1.1778 g/cm3 (Estimated) | 
| 颜色 | White | 
| 物理性状 | Solid | 
| 存储 | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | Ethanol: 40 mg/mL (135.41 mM), Sonication is recommended.  DMSO: 80 mg/mL (270.82 mM), Sonication is recommended.  | |||||||||||||||||||||||||||||||||||
| 溶液配制表 | ||||||||||||||||||||||||||||||||||||
| Ethanol/DMSO 
 | ||||||||||||||||||||||||||||||||||||
 比如您的给药剂量是 10 mg/kg ,每只动物体重 20 g ,给药体积 100 μL ,
比如您的给药剂量是 10 mg/kg ,每只动物体重 20 g ,给药体积 100 μL ,  一共给药动物 10 只 ,您使用的配方为 5%
 一共给药动物 10 只 ,您使用的配方为 5%  DMSO+ 30%PEG300+ 5%Tween 80 + 60%Saline/PBS/ddH2O, 那么您的工作液浓度为 2 mg/mL 。
DMSO+ 30%PEG300+ 5%Tween 80 + 60%Saline/PBS/ddH2O, 那么您的工作液浓度为 2 mg/mL 。 
评论内容